Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) generates a steady flow of news across Innovative Medicine and MedTech, reflecting its role in pharmaceutical preparation manufacturing and medical technologies. On this news page, readers can follow company announcements on clinical trial results, regulatory milestones, strategic transactions, manufacturing investments and corporate actions.
Recent oncology news includes positive topline data from the Phase 3 MajesTEC-9 study of TECVAYLI (teclistamab-cqyv) monotherapy in relapsed or refractory multiple myeloma, where Johnson & Johnson reported a substantial reduction in the risk of disease progression or death versus standard of care in a population predominantly refractory to anti-CD38 therapy and lenalidomide. The company has also shared longer-term results from the OrigAMI-1 study of RYBREVANT (amivantamab-vmjw) plus chemotherapy in metastatic colorectal cancer, supporting further Phase 3 evaluation of amivantamab-based regimens in first- and second-line settings.
In neuroscience and mental health, Johnson & Johnson has highlighted new data on CAPLYTA (lumateperone), SPRAVATO (esketamine) and the investigational agent seltorexant at major scientific meetings, including analyses focused on remission in major depressive disorder, treatment-resistant depression and sleep-related symptoms. The company has also announced positive Phase 2b results for nipocalimab in systemic lupus erythematosus and plans to initiate a Phase 3 program, underscoring its activity in autoantibody-driven diseases.
MedTech news covers developments such as the FDA submission of the OTTAVA robotic surgical system for De Novo classification, supported by an IDE study in gastric bypass procedures, and an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for chronic subdural hematoma. Corporate and financial updates, including quarterly dividend declarations, U.S. manufacturing investments and government agreements to improve access to medicines, also appear in Johnson & Johnson’s news flow. Investors, clinicians and observers can use this page to monitor how Johnson & Johnson’s clinical, regulatory and strategic decisions evolve over time.
The Third Circuit Court has denied a rehearing request regarding Johnson & Johnson's (NYSE:JNJ) bankruptcy petition related to talcum powder litigation, determining it was not filed in good faith. This decision enables over 38,000 lawsuits alleging links between J&J's talc products and cancer to resume. The court found that J&J's use of the Texas Two-Step bankruptcy strategy to limit claims was not justified and indicated that LTL, its subsidiary, was not in financial distress. The firm plans to cease production of talc-based products globally amid ongoing litigation and regulatory scrutiny over the potential carcinogenic effects of talc.
Johnson & Johnson (NYSE: JNJ) will host a conference call on April 18, 2023, at 8:30 a.m. (Eastern Time) to discuss its first-quarter results. Key executives, including Joseph J. Wolk and Jessica Moore, will lead the call, which will also include a Q&A session. Investors can join via webcast at www.investor.jnj.com or by dialing specific numbers for U.S. and international participants. A replay will be available until May 3, 2023. The press release with detailed financial results will be published at approximately 6:45 a.m. (Eastern Time) on the same day.
The Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) published new data in Nature demonstrating that JNJ-1802, an antiviral candidate, is effective against dengue in non-human primates and mice. Following successful Phase 1 trials showing safety and tolerability in humans, JNJ-1802 is progressing to Phase 2 studies. The data revealed efficacy against all four dengue serotypes, particularly DENV-1 and DENV-2. Given the rising global dengue threat due to climate change, the findings emphasize the urgent need for antiviral solutions to combat this disease.
Johnson & Johnson (NYSE: JNJ) announced that its subsidiary Kenvue Inc. has priced an offering of senior unsecured notes totaling $7.75 billion. The notes have varying maturities and coupon rates, with the first series due 2025 at 5.500%. The proceeds will partially fund Kenvue's acquisition of Johnson & Johnson's Consumer Health Business. The offering is not contingent upon the separation's completion, expected around March 22, 2023. The notes will be guaranteed by Johnson & Johnson until the separation and registration of Kenvue's equity securities occur. The securities have not been registered under U.S. laws.
AtlantiCare has become the first healthcare system in the northeastern U.S. to implement the Optellum Virtual Nodule Clinic, enhancing early lung cancer diagnosis through AI technology. Located in New Jersey, this initiative is part of AtlantiCare's lung cancer program at the AtlantiCare Regional Medical Center. The platform aids in identifying and tracking at-risk patients, with the ability to biopsy concerning lesions early, potentially improving outcomes. With approximately 50 out of 300 patients flagged for surveillance, this partnership demonstrates the critical need for early-stage detection in lung cancer.
Johnson & Johnson (NYSE: JNJ) has appointed Dr. Paula A. Johnson, President of Wellesley College, to its Board of Directors. CEO Joaquin Duato welcomed her, citing her extensive knowledge in medical research and public health, which is expected to enhance the board’s expertise. Dr. Johnson expressed her commitment to improving health outcomes globally. With significant experience in academic medicine and leadership roles, including founding the Connors Center for Women’s Health, she is set to bring a valuable perspective as JNJ continues its mission of advancing healthcare.
Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global HealthCare Conference on Tuesday, March 14, at the Loews Miami Beach Hotel in Miami Beach, Florida. Company Group Chairmen Aldo Denti from DePuy Synthes and Peter Menziuso from Vision will represent the company at 10:15 a.m. (Eastern Time). Investors can access the live audio webcast on the Johnson & Johnson website. A replay of the audio webcast will be available approximately 48 hours after the event.
Johnson & Johnson (NYSE: JNJ) has appointed Dr. John Reed as Executive Vice President of Pharmaceuticals, R&D, effective April 3, 2023. Dr. Reed brings over 35 years of experience in biomedical research, having previously served as Executive Vice President at Sanofi. He succeeds Dr. William Hait, who led the Pharmaceutical R&D organization on an interim basis since August 2022. CEO Joaquin Duato expressed confidence in Dr. Reed's capabilities to enhance innovation and competitiveness within the company. Dr. Reed has been instrumental in bringing multiple medicines to market during his career and aims to prioritize patient needs at Johnson & Johnson.
Biosense Webster, part of Johnson & Johnson MedTech, announced positive interim results from the inspIRE clinical study at the 28th Annual International AF Symposium. The study evaluated the safety and efficacy of the VARIPULSE™ Catheter and TRUPULSE™ Generator in treating recurrent paroxysmal atrial fibrillation (AF). Out of 226 enrolled patients across 13 centers, the study achieved an impressive 70.9% primary efficacy endpoint with 78.9% freedom from AF recurrence at 12 months. No serious adverse events were reported. The investigational device aims to provide a safer ablation technique, potentially reducing risks associated with traditional treatments.
Biosense Webster, part of Johnson & Johnson MedTech, announced positive results from the STELLAR study, presented at the 28th Annual International AF Symposium. This study evaluated the HELIOSTAR™ Balloon Ablation Catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AFib). Key findings include an acute pulmonary vein isolation (PVI) rate of 98.8%, with 67.7% primary effectiveness at 12 months. Furthermore, over 90% of participants remained free from repeat ablation after one year, with a clinical success rate of 77.7%. The HELIOSTAR™ is the first radiofrequency balloon catheter approved in EMEA for cardiac ablation.